生命科学资讯

Cybin alters state to become Helus Pharma for Nasdaq trip

Merck turns down option to Evaxion's gonorrhea vaccine, prompting Danish biotech to seek other partners

Galapagos ends turbulent year with mixed results for last remaining immunology asset

Boehringer walks away from Nxera's phase 2-ready schizophrenia program

Moon Surgical enters new phase, updating robots with AI connectivity

Karuna head, Teva alums meet minds to launch schizophrenia-focused biotech Syremis with $165M series A

GlucoModicum touts needle-free Sofio glucose monitoring patch

Verge Genomics drops sole clinical candidate in return to AI drug discovery roots

GSK pays $17.5M for CAMP4 regulatory RNA deal

Takeda looks to 2026 FDA filing for its Sotyktu rival zasocitinib after phase 3 success

Lilly's obesity pill largely maintains weight lost on injectable GLP-1s

After HHS funding was scrapped, CEPI fronts up to $54M to carry Moderna's pandemic influenza vaccine into phase 3

Lindus Health and Quotient team up to create one-stop shop for early to mid-stage trials

Voyager jettisons 30 employees, Novartis hands back rights to 2 programs

Oncology biotech Mythic and former fundraising heavyweight Areteia reach end of road

CMR Surgical grabs FDA clearance for upgraded Versius Plus robot

Norgine gets in on Vir's hepatitis D program with €550 European licensing pact

Fired NIH institute director sues Trump health officials, seeks reinstatement and backpay

Vistagen phase 3 study sees placebo surprise, putting future of social anxiety asset into question: analyst

Addition Tx does the math and emerges from stealth with $100M, biotech vets on exec team